focus -WSS

focus

author：fashion 2025-08-12 06:42:55 - browse：1449

Photograph of Bill Cassidy. -- health policy coverage from STAT — Sen. Bill Cassidy (R-La.) Kevin Dietsch/Getty Images

WASHINGTON — With Novo Nordisk’s Wegovy and Ozempic hitting blockbuster sales and a new rival approved this week, everyone in Washington is thinking about how to manage the crashing wave of weight loss drug costs.

The explosive national demand for weight management therapies and diabetes drugs like Ozempic — all of which are indicated for indefinite use — has become central in an ongoing policy debate over high drug costs and controversial tactics to manage them, including President Biden’s plan to let the government negotiate directly with pharmaceutical companies. Seventy percent of Americans could qualify for these medicines.

Sen. Bill Cassidy (R-La.), the highest-ranking Republican on the Senate’s health policy committee, has vehemently opposed the negotiation plan, arguing it reduces incentives to develop new therapies and may not actually reduce patients’ costs.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Medicare Advantage plans can’t deny care with AI, CMS warns

WSS

Solving academic medical centers' existential crisis

Bird flu: Don't repeat Covid's 'health versus the economy' framing

Readout LOUD: Venture capital, Gilead, and more M&A

Top private equity targets in 2023: cardiology, clinical trials, lasers

Data integrity in scientific journals requires "effort" by publishers, institutions

Cytokinetics CEO stresses company can launch heart drug on its own

hotspot

focus

focus

Hepatitis C has a cure — but many Americans still lack access to it

NVIDIA and Google execs on the future of AI and drug discovery

23andMe had bad news about my health. I wish a person had delivered it

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

Guidelines to prevent youth baseball injuries need more muscle

Unique patient identifier: Experts argue the benefits, pitfalls

Heart attack and stroke risk calculators need revising

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

BioMarin wins approval for gene therapy to treat hemophilia A

Medicare Advantage plans can’t deny care with AI, CMS warns

hotspot

Bird flu: Don't repeat Covid's 'health versus the economy' framing

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Readout LOUD: Venture capital, Gilead, and more M&A

Adopting new red light myopia treatments may be short

Why CTE doesn’t keep Americans from enjoying the Super Bowl

What’s missing from the debate over nursing home staff minimums

leisure time

focus

Wikipedia

explore